Sopharma Valuation Multiples

Sopharma is valued at $1.6B as of October 2026, a 1.2x revenue multiple. In the last 12 months, Sopharma revenue was $1.6B and Sopharma EBITDA was $133M.

Sopharma Overview

About Sopharma

Sopharma AD-Sofia is a company engaged in the production of pharmaceutical products. Its principal activities include the production and trade of medicinal substances and finished drug forms; and research and development as well as engineering and implementation activities in the field of medicinal products. It is also focused on the distribution of pharmaceuticals like medical supplies, sanitary materials, vitamins, food supplements, and cosmetics. The company's segments are the Production of pharmaceutical products; Distribution of pharmaceutical products. It generates the majority of its revenue from the Distribution of pharmaceutical products.


Founded

1933

HQ

Bulgaria

Employees

5.6K

Financials (LTM)

Revenue: $1.6B
EBITDA: $133M

EV

$1.9B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Sopharma Financials

Sopharma reported last 12-month revenue of $1.6B and EBITDA of $133M.

In the same LTM period, Sopharma generated $778M in gross profit, $133M in EBITDA, and $86M in net income.

Revenue (LTM)


Sopharma P&L

In the most recent fiscal year, Sopharma reported revenue of $1.5B and EBITDA of $145M.

Sopharma is profitable as of last fiscal year, with gross margin of 23%, EBITDA margin of 10%, and net margin of 5%.

See analyst estimates for Sopharma
LTMLast FY202320242025202620272028
Revenue$1.6B$1.5B$1.1B$1.3B$1.5B
Gross Profit$778M$348M$240M$269M$348M
Gross Margin49%23%22%21%23%
EBITDA$133M$145M$103M$96M$145M
EBITDA Margin8%10%9%8%10%
EBIT Margin6%6%5%4%6%
Net Profit$86M$74M$57M$45M$74M
Net Margin5%5%5%4%5%
Net Debt-$254M---

Financial data powered by Morningstar, Inc.

Sopharma Stock Performance

Sopharma has current market cap of $1.6B, and enterprise value of $1.9B.

Market Cap Evolution


Sopharma's stock price is $2.94.

Sopharma share price decreased by 0.3% in the last 30 days, and increased by 78.8% in the last year.

Sopharma has an EPS (earnings per share) of $0.14.

See more trading valuation data for Sopharma
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$1.9B$1.6B-0.7%-0.3%32.1%78.8%$0.14

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Sopharma Valuation Multiples

Sopharma trades at 1.2x EV/Revenue multiple, and 14.2x EV/EBITDA.

See NTM and 2027E valuation multiples for Sopharma

EV / Revenue (LTM)


Sopharma Financial Valuation Multiples

As of October 9, 2026, Sopharma has market cap of $1.6B and EV of $1.9B.

Sopharma has a P/E ratio of 18.4x.

LTMLast FY202320242025202620272028
EV/Revenue1.2x1.3x1.7x1.5x1.3x
EV/EBITDA14.2x13.0x18.4x19.6x13.0x
EV/EBIT21.1x22.7x32.5x37.0x22.7x
EV/Gross Profit2.4x5.4x7.9x7.0x5.4x
P/E18.4x21.4x27.8x35.0x21.4x
EV/FCF-(25.7x)n/m(70.2x)(25.7x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Sopharma Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Sopharma Margins & Growth Rates

Sopharma grew revenue by 12% but EBITDA decreased by 3% in the last fiscal year.

In the most recent fiscal year, Sopharma reported gross margin of 23%, EBITDA margin of 10%, and net margin of 5%.

See estimated margins and future growth rates for Sopharma

Sopharma Margins

Last FY202420252026202720282029
Gross Margin23%21%23%-
EBITDA Margin10%8%10%9%
EBIT Margin6%4%6%6%
Net Margin5%4%5%5%
FCF Margin(5%)(2%)(5%)-

Sopharma Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth12%14%18%12%
Gross Profit Growth-12%30%-
EBITDA Growth(3%)(6%)51%(3%)
EBIT Growth15%(12%)63%15%
Net Profit Growth23%(20%)63%23%
FCF Growth-(3641%)173%-

Data powered by FactSet, Inc. and Morningstar, Inc.

Sopharma Operational KPIs

Sopharma's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.0M for the same period.

Sopharma's Rule of 40 is 20% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Sopharma's Rule of X is 37% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Sopharma
LTMLast FY202320242025202620272028
Rule of 4014%20%---
Bessemer Rule of X22%37%---
Revenue per Employee-$0.3M---
Opex per Employee-$0.0M---
S&M Expenses to Revenue-2%2%3%2%
G&A Expenses to Revenue-1%1%1%1%
Opex to Revenue-18%16%17%18%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
Chengzhi$1.6B$129M1.3x1.3x16.6x-
Inner Mongolia Furui Medical Science$238M$65M6.8x5.7x24.9x20.7x
Kestra Medical Technologies$95M($123M)14.9x12.2x(11.5x)(16.3x)
Dentsply Sirona$3.7B($46M)1.0x1.1x(82.7x)6.0x
BioLife Solutions$96M($10M)18.9x16.5x(180.4x)64.2x
Shinva$1.5B$127M0.6x0.6x7.3x7.3x
Gerresheimer$2.6B$55M1.3x1.3x61.6x7.4x
Menicon$794M$128M1.5x1.4x9.1x8.4x

This data is available for Pro users. Sign up to see all Sopharma competitors and their valuation data.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Sopharma

When was Sopharma founded?Sopharma was founded in 1933.
Where is Sopharma headquartered?Sopharma is headquartered in Bulgaria.
How many employees does Sopharma have?As of today, Sopharma has over 5K employees.
Is Sopharma publicly listed?Yes, Sopharma is a public company listed on Bulgarian Stock Exchange.
What is the stock symbol of Sopharma?Sopharma trades under SFA ticker.
When did Sopharma go public?Sopharma went public in 2000.
Who are competitors of Sopharma?Sopharma main competitors include Chengzhi, Inner Mongolia Furui Medical Science, Kestra Medical Technologies, Dentsply Sirona, BioLife Solutions, Shinva, Gerresheimer, Menicon, Standard Engineering Tech, Paul Hartmann.
What is the current market cap of Sopharma?Sopharma's current market cap is $1.6B.
What is the current revenue of Sopharma?Sopharma's last 12 months revenue is $1.6B.
What is the current revenue growth of Sopharma?Sopharma revenue growth (NTM/LTM) is 6%.
What is the current EV/Revenue multiple of Sopharma?Current revenue multiple of Sopharma is 1.2x.
What is the current EBITDA of Sopharma?Sopharma's last 12 months EBITDA is $133M.
What is Sopharma's EBITDA margin?Sopharma's last 12 months EBITDA margin is 8%.
What is the current EV/EBITDA multiple of Sopharma?Current EBITDA multiple of Sopharma is 14.2x.
How many companies Sopharma has acquired to date?Sopharma hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Sopharma has invested to date?Sopharma hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Sopharma

Lists including Sopharma

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial